Table 3.
Patient and tumor characteristics of the NF1 and Family History Clinic populations included in the delayed entry analyses
| Non-NF1 | All NF1 | NF1 excluding Padova | NF1, Finland | NF1, Hamburg | NF1, Manchester | NF1, Padova | NF1, Paris | |
|---|---|---|---|---|---|---|---|---|
| Total (n) | 335 | 137 | 110 | 45 | 15 | 31 | 27 | 19 |
| Died (n) | 32 | 53 | 51 | 25 | 3 | 19 | 2 | 4 |
| Died of breast cancer (n) | 24 | 25 | 25 | 10 | 3 | 11 | 0 | 1 |
| Contralateral breast cancer (n) | 21 | 12 | 10 | 2 | 2 | 4 | 2 | 2 |
| ER+/ER− (n/n) | 217/83 | 51/24 | 40/23 | 15/14 | 9/3 | 11/5 | 11/1 | 5/1 |
| ER+ (%) | 72.3 | 68.0 | 63.5 | 51.7 | 75.0 | 68.8 | 91.7 | 83.3 |
| Missing (n [%]) | 35 (10.4%) | 62 (45.3%) | 47 (42.7%) | 16 (35.6%) | 3 (20.0%) | 15 (48.4%) | 15 (55.6%) | 13 (68.4%) |
| HER2+/HER2− (n/n) | 14/112 | 16/51a | 14/44a | 9/19 | 0/8 | 5/11 | 2/7 | 0/6 |
| HER2+ (%) | 11.1 | 23.9 | 24.1 | 32.1 | 0.0 | 31.3 | 22.2 | 0.0 |
| Missing (n [%]) | 209 (62.4%) | 70 (51.1%) | 52 (47.3%) | 17 (37.8%) | 7 (46.7%) | 15 (48.4%) | 18 (66.7%) | 13 (68.4%) |
| Grade 1/2/3 (n/n/n) | 39/118/157 | 12/33/44 | 9/26/42 | 2/13/18 | 3/7/4 | 2/5/15 | 3/7/2 | 2/1/5 |
| Grade 1 (%) | 12.4 | 13.5 | 11.7 | 6.1 | 21.4 | 9.1 | 25.0 | 25.0 |
| Grade 2 (%) | 37.6 | 37.1 | 33.8 | 39.4 | 50.0 | 22.7 | 58.3 | 12.5 |
| Grade 3 (%) | 50.0 | 49.4 | 54.5 | 54.5 | 28.6 | 68.2 | 16.7 | 62.5 |
| Missing (n [%]) | 21 (6.3%) | 48 (35.0%) | 33 (30.0%) | 12 (26.7%) | 1 (6.7%) | 9 (29.0%) | 15 (55.6%) | 11 (57.9%) |
| Stage 1/invasive (n/n) | 163/275 | 27/104b | 18/88b | 8/37 | 5/14 | 1/28 | 9/16 | 4/9 |
| Stage 1 of invasive (%) | 59.3 | 26.0 | 20.5 | 21.6 | 35.7 | 3.6 | 56.3 | 44.4 |
| CIS (n) | 58 | 9a | 7a | 3 | 1 | 3 | 2 | 0 |
| CIS (%) | 17.4 | 8.0 | 7.4 | 7.5 | 6.7 | 9.7 | 11.1 | 0.0 |
| Missing (n [%]) | 2 (0.6%) | 24 (17.5%) | 15 (13.6) | 5 (11.1%) | 0 (0.0%) | 0 (0.0%) | 9 (33.3%) | 10 (52.6%) |
| Mean age (SD) at first breast cancer (years) | 48.3 (7.7) | 48.2 (10.5) | 48.2 (10.9) | 49.1 (12.3) | 48.1 (8.3) | 47.2 (10.8) | 48.0 (9.0) | 47.9 (9.8) |
| Mean age (SD) at contralateral breast cancer (years) | 53.4 (9.8) | 51.4 (9.8) | 51.0 (10.8) | 62.5 (0.4) | 51.6 (13.7) | 43.7 (10.7) | 53.0 (0.0) | 53.6 (3.9) |
| Mean age (SD) at cohort entry (years) | 41.4 (8.3) | 44.4 (14.2) | 45.6 (13.8) | 43.7 (16.3) | —c | 46.4 (11.9) | 40.1 (15.0) | 48.9 (9.8) |
| Mean age (SD) at death (years) | 54.4 (8.9) | 56.2 (14.6) | 56.1 (14.9) | 58.4 (16.4) | 55.2 (8.5) | 52.4 (13.1) | 58.4 (2.0) | 60.5 (17.2) |
| Mean age (SD) at end of follow-up (years) | 55.6 (11.0) | 57.1 (12.0) | 57.1 (12.4) | 59.0 (14.5) | 58.6 (9.7) | 52.9 (11.6) | 56.8 (10.5) | 58.4 (8.9) |
| Mean follow-up (SD) in delayed entry (years) | 7.3 (6.9) | 6.5 (5.7) | 6.5 (5.9) | 7.4 (6.0) | 10.5 (7.6) | 3.5 (4.3) | 6.5 (5.1) | 6.0 (4.1) |
CIS carcinoma in situ,ER estrogen receptor, NF1 neurofibromatosis 1.
aNF1 or NF1 excluding Padova compared with the non-NF1 group from Manchester Family History Clinic, Fisher's exact test, 0.05 > P > 0.01.
bNF1 or NF1 excluding Padova compared with the non-NF1 group from Manchester Family History Clinic, Fisher's exact test, P < 0.0001.
cAll patients entered the cohort before the breast cancer but no exact age at cohort entry is available.